Business Context and Reporting Period
This Form 8-K Current Report was filed by Supernus Pharmaceuticals, Inc. on November 11, 2019. The report covers events occurring on November 11 and November 12, 2019, regarding regulatory submissions and investor relations activities.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate events rather than financial performance data.
Material Changes and Events
- Regulatory Submission: On November 11, 2019, the Company submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for SPN-812, intended for the treatment of patients with attention deficit hyperactivity disorder (ADHD).
- Investor Relations: On November 12, 2019, the Company announced management presentations at the Stifel 2019 Healthcare Conference in New York (November 19) and the Jefferies 2019 London Healthcare Conference (November 21).
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, management commentary on future performance, or a discussion of risks and contingencies beyond the standard regulatory process implied by the NDA submission. The primary outlook is tied to the FDA's review of the SPN-812 application.
Key Facts for Investor Verification
- Verify the status and expected timeline of the FDA review for the SPN-812 NDA.
- Review the full text of the press releases (Exhibits 99.1 and 99.2) for detailed clinical data or specific indications regarding SPN-812.
- Monitor the outcomes of the upcoming investor presentations at the Stifel and Jefferies conferences for updated strategic direction.